PRL-01

PRL-01 is an investigational **small molecule** drug being developed by **Propella Therapeutics** for **herpes simplex virus infections**, with public pipeline sources specifically linking it to **herpes simplex** and **cold sores**. Publicly available information indicates that the program remained in the **preclinical** stage, but detailed disclosure of its molecular identity, precise biological target, formulation, route, and mechanism of action has not been found in accessible primary or company-level public materials. Based on the available evidence, PRL-01 appears to be a proprietary antiviral candidate in Propella's pipeline rather than an approved or clinically characterized product.